Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Acute Effects of Jägermeister With Energy Drinks (Jägermbomb) (JB)

perjantai 8. toukokuuta 2026 päivittänyt: Fundació Institut Germans Trias i Pujol

Acute Effects of an Explosive Cocktail With Energy Drinks That is Trendy Among Young People, the Jägerbomb

The main objective of this study is to compare the acute effects of drinking Jägerbombs with drinking alcohol alone during a binge-drinking episode, which involves consuming a large amount of alcohol in a short period of time to become intoxicated. Secondary objectives are to assess whether Jägerbombs produce prototypical alcohol effects, increase stimulation and rewarding effects, affect coordination, time reaction and vision, change stress-related hormone responses, and cause hangover symptoms.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Alcohol use is very common among young people in Spain. Binge drinking is a pattern of alcohol consumption that raises blood alcohol concentration (BAC) to 0.08% or higher (0.4 mg/L in breath air), typically defined as drinking 5 or more standard drinks for men or 4 or more for women within about 2 hours.This is a serious public health problem because it can cause illness, injuries, and even death.

Energy drinks (ED) are also widely used by young people and are often mixed with alcohol. People do this to hide the taste of alcohol or to feel less tired or drunk. However, ED do not reduce alcohol intoxication and are linked to more risky behavior. Research suggests that ED only slightly reduce some alcohol-related problems, such as slower reactions. This can give a false feeling of safety and make people more likely to drive while drunk.

One popular mixture is the Jägerbomb, a combination of Jägermeister liquor and energy drink (ED), but its effects have not been previously studied.

This study will be conducted as a randomized, double-blind, placebo-controlled trial in healthy adults who have experience consuming alcohol and caffeinated beverages.

A pilot study has been conducted in the first four participants (two women and two men) using a dose of 55 g of alcohol.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

24

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

      • Barcelona, Espanja
        • Rekrytointi
        • Hospital Universitari Germans Trias i Pujol-IGTP
        • Päätutkija:
          • Clara Pérez-Mañá, MD, PhD
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen

Hyväksyy terveitä vapaaehtoisia

Joo

Kuvaus

Inclusion Criteria:

  1. Men and women between 18-45 years old with a weight between 50-90 kg for men and between 55-80 kg for women, and a body mass index (BMI) between 19-28 kg/m2. Lower or higher weights or BMIs are allowed, in the opinion of the Principal Investigator or the collaborators designated by the Principal Investigator and that do not pose a risk to the subjects and do not interfere with the objectives of the study.
  2. Alcohol consumption in the form of occasional binge drinking (≥1 time/month), social alcohol consumption (≥10g/day distributed weekly) and experience in alcohol intoxication.
  3. Consumption ≥7 drinks with methylxanthines (coffee, tea, chocolate, cola, BE) per week and who have consumed ED on at least one occasion.
  4. Understand and agree to the trial procedures and sign an informed consent.
  5. History and physical examination that demonstrate no organic or psychiatric disorders.
  6. The ECG and general blood and urine tests performed before the test should be within normal limits. Minor or punctual variations from the limits of normality are allowed if, at the discretion of the Principal Investigator, taking into account the state of science, they are not of clinical significance, do not pose a risk to the subjects and do not interfere with the assessment of the product. These variations and their non-relevance will be justified in writing in a specific way.

Exclusion Criteria:

  1. Not meeting the inclusion criteria.
  2. History or clinical evidence of gastrointestinal, liver, renal or other disorders that may involve an alteration in the absorption, distribution, metabolism or excretion of the drug, or that are suggestive of gastrointestinal irritation by drugs.
  3. Current history of substance use disorder according to DSM-V (except nicotine). A previous history of mild substance use disorder (corresponding to substance abuse according to DSM-IV criteria) is admitted.
  4. History or clinical evidence of psychiatric disorders, alcoholism, abuse of drugs or other drugs or habitual consumption of psychoactive drugs.
  5. Have participated in clinical trials with drugs or nutraceuticals in the previous 12 weeks.

5) Have suffered any organic disease or major surgery in the three months prior to the start of the study.

6) Subjects who have an intolerance or have had serious adverse reactions to alcohol. The inclusion of subjects of oriental origin who do not have an intolerance to alcohol will be allowed.

7) Have taken medication regularly in the month prior to the study sessions, with the exception of vitamins, herbal remedies, or dietary supplements that, in the judgment of the Principal Investigator or collaborators designated by the Principal Investigator, do not pose a risk to the subjects and do not interfere with the objectives of the study. Treatment with single doses of symptomatic medication in the week prior to study sessions will not be grounds for exclusion if it is assumed to have been completely eliminated on the day of the experimental session.

8) Smokers of >5 cigarettes a day. 9) Consumption of more than 20 g of alcohol daily in women and more than 40 g in men.

10) Consumers of more than 5 coffees, teas, colas, or other stimulant or xanthine beverages daily in the 3 months prior to the start of the study.

11) Subjects who are not able to understand the nature of the trial and the procedures they are asked to follow.

12) Subjects with positive serology for hepatitis B, C or HIV. 13) Women who are pregnant or breastfeeding, or who use hormonal contraceptives or do not use reliable contraceptive measures during the study (such as abstinence, intrauterine devices, barrier methods or with a vasectomized partner).

14) Women with amenorrhea or premenstrual syndrome of severe intensity.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Perustiede
  • Jako: Satunnaistettu
  • Inventiomalli: Crossover-tehtävä
  • Naamiointi: Kaksinkertainen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Alcohol (Jägermeister) and Energy Drink: Jägerbomb
The total volume of drink is 821 mL in women and 875 mL in men, and is divided into 5 doses simulating a binge pattern, administered every 10 min (total time 45 minutes). Women: Jägermeister 196 mL (ethanol 55 g) + ED 625 ml (200 mg caffeine). Men: Jägermeister 250 mL (ethanol 70 g) + ED 625 ml (200 mg caffeine)
Multiple oral dose of Jägermeister mixed with ED
Active Comparator: Alcohol (Jägermeister) and Energy Drink Placebo
The total volume of drink is 821 mL in women and 875 mL in men, and is divided into 5 doses simulating a binge pattern, administered every 10 min (total time 45 minutes). Women: Jägermeister 196 mL (55 g of ethanol) + placebo ED (a non-caffeinated soft drink) 625 mL. Men: Jägermeister 250 mL (70 g) + placebo ED (a non-caffeinated soft drink) 625 mL.
Multiple oral dose of Jägermeister mixed with a placebo of ED (non-caffeinated soft drink)
Placebo Comparator: Alcohol placebo and Energy Drink Placebo
The total volume of drink is 821 mL in women and 875 mL in men, and is divided into 5 doses simulating a binge pattern, administered every 10 min (total time 45 minutes). Women: Ethanol placebo (water) + ED placebo (a non-caffeinated soft drink) 625 mL. Men: Ethanol placebo (water) + ED placebo (a non-caffeinated soft drink) 625 mL.
Multiple oral dose of alcohol placebo (water) mixed with ED placebo (non-caffeinated soft drink)

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in reaction time (Psychomotor Vigilance Task)
Aikaikkuna: From baseline to 4 hours after administration
Test will be performed using a computer program. Mean and median latency will be assessed. Obtained baseline, 1.5 and 4-h after administration.
From baseline to 4 hours after administration

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Aika etanolin enimmäispitoisuuden (tmax) saavuttamiseen hengitysilmassa
Aikaikkuna: Lähtötilanteesta 8 tuntiin annon jälkeen
Aika etanolin enimmäispitoisuuden (tmax) saavuttamiseen hengitysilmassa
Lähtötilanteesta 8 tuntiin annon jälkeen
Maximum concentration (Cmax) of ethanol in breath air
Aikaikkuna: From baseline to 8 hours after administration
Maximum concentration (Cmax) of ethanol in breath air
From baseline to 8 hours after administration
Maximum concentration (Cmax) of caffeine in oral fluid
Aikaikkuna: From baseline to 6 hours after administration
Maximum concentration (Cmax) of caffeine in oral fluid
From baseline to 6 hours after administration
Area under the concentration-time curve (AUC 0-8h) of ethanol breath concentrations
Aikaikkuna: From baseline to 8 hours after administration
Obtained baseline and 0.17, 0.33 , 0.5, 0.66, 0,83, 1, 1.25, 1.5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Area under the concentration-time curve (AUC 0-6h) of caffeine oral fluid concentrations
Aikaikkuna: From baseline to 6 hours after administration
Calculation of AUC of caffeine concentrations obtained baseline and 1, 1.5, 2, 4, 6-h after administration.
From baseline to 6 hours after administration
Time to reach maximum concentration (tmax) of caffeine in oral fluid
Aikaikkuna: From baseline to 6 hours after administration
Time to reach maximum concentration (tmax) of caffeine in oral fluid
From baseline to 6 hours after administration
Maximum concentration (Cmax) of cortisol in oral fluid
Aikaikkuna: From baseline till 6 hours after administration
Maximum concentration (Cmax) of cortisol in oral fluid
From baseline till 6 hours after administration
Time to reach maximum concentration (tmax) of saliva in oral fluid
Aikaikkuna: From baseline to 6 hours after administration
Time to reach maximum concentration (tmax) of saliva in oral fluid
From baseline to 6 hours after administration
Area under the concentration-time curve (AUC 0-6h) of cortisol concentrations in oral fluid
Aikaikkuna: From baseline till 6 hours after administration
Calculation of AUC of cortisol oral fluid concentrations. Obtained baseline and 1, 1.5 , 2, 4, 6-h after administration.
From baseline till 6 hours after administration
Change in visual acuity
Aikaikkuna: From baseline to 4 hours after administration
A computer program will be used to measure static and dynamic visual acuity with different contrast (100% and 10%) at baseline, 2 and 4-h after administration
From baseline to 4 hours after administration
Change in unstable tracking task
Aikaikkuna: From baseline to 4 hours after administration
Test will be performed using a computer program. Mean lambda and number of errors will be measured. Obtained baseline and 1.5, 4-h after administration.
From baseline to 4 hours after administration
Change in pupillary diameter
Aikaikkuna: From baseline to 4 hours after administration
Pupillary diameter will be measured with a manual pupilometer
From baseline to 4 hours after administration
Change in drowsiness feeling
Aikaikkuna: From baseline to 8 hours after administration
Drowsiness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in drunkenness feeling
Aikaikkuna: From baseline to 8 hours after administration
Drunkenness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration
From baseline to 8 hours after administration
Change in dizziness feeling
Aikaikkuna: From baseline to 8 hours after administration
Dizziness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration
From baseline to 8 hours after administration
Change in palpitations reported by the participant
Aikaikkuna: From baseline to 8 hours after administration
Palpitations will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in anxiety feeling
Aikaikkuna: From baseline to 8 hours after administration
Anxiety will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in headache
Aikaikkuna: From baseline to 8 hours after administration
Headache will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in ability and predisposition to drive in certain situations
Aikaikkuna: From baseline to 6 hours after administration
Will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 1.5, 4, 6-h after administration.
From baseline to 6 hours after administration
Desire to keep drinking
Aikaikkuna: At 1.5 hours after administration
Will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained at the end of beverage administration. Only one measure at 1.5 hours.
At 1.5 hours after administration
Change in subjective effects measured with Addiction Research Center Inventory (ARCI)
Aikaikkuna: From baseline to 8 hours after administration
Obtained baseline and 1, 2, 4, 6 and 8-h after administration
From baseline to 8 hours after administration
Change in blood pressure
Aikaikkuna: From baseline to 8 hours after administration
Systolic and diastolic blood pressure (mmHg) will be measured obtained baseline and 0.5, 1, 1,5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in heart rate
Aikaikkuna: From baseline to 8 hours after administration
Heart rate (bpm) will be measured obtained baseline and 0.5, 1, 1,5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in oral temperature
Aikaikkuna: From baseline to 8 hours after administration
Oral temperature (ºC) will be measured obtained baseline and 0.5, 1, 1,5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in Maddox Wing score (MW)
Aikaikkuna: From baseline to 4 hours after administration
Maddox wing is a device for the measurement of diopters of horizontal heterophoria. From 22 (exophoria) to 15 (esophoria). Higher scores mean worse outcome.Obtained baseline and 1.5, 4-h after administration.
From baseline to 4 hours after administration
Hangover
Aikaikkuna: At 8 hours and 12 hours after administration
Measured at 8 and 12h , with Alcohol Hangover Severity Scale
At 8 hours and 12 hours after administration
Change in anxiety
Aikaikkuna: From baseline to 6 hours after administration
Measured with Anxiety-state scale (STAI-S) at baseline, 1,1,4, 6-h after administration
From baseline to 6 hours after administration
Beverage identification
Aikaikkuna: At 8 hours after administration
Beverage identification questionnaire.There is an option to select each treatment condition. Only measured at 8h after administration
At 8 hours after administration
Urine volume generated
Aikaikkuna: From baseline to 8 hours after administration
Mililiters of urine collected
From baseline to 8 hours after administration

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Clara Pérez Mañá, MD, PhD, Hospital Universitari Germans Trias i Pujol-IGTP

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Keskiviikko 18. helmikuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Maanantai 1. maaliskuuta 2027

Opintojen valmistuminen (Arvioitu)

Tiistai 1. kesäkuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 4. toukokuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 8. toukokuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Torstai 14. toukokuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 14. toukokuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 8. toukokuuta 2026

Viimeksi vahvistettu

Keskiviikko 1. huhtikuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

IPD-suunnitelman kuvaus

IPD will not be shared as the dataset is subject to ongoing analyses and planned future publications.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa